Second‐trimester maternal serum screening for Down syndrome in <i>in vitro</i> fertilization pregnancies

Abstract

IVF patients can be counselled about maternal serum triple marker screening in the same manner as patients with naturally conceived pregnancies. There is no evidence to support the general use of analyte correction factors in the interpretation of second-trimester maternal serum screen results in IVF pregnancies.